Logo

Daiichi Sankyo Initiates P-I Study of DS-1055 for Relapsed/Refractory Advanced or Metastatic Solid Tumors

Share this

Daiichi Sankyo Initiates P-I Study of DS-1055 for Relapsed/Refractory Advanced or Metastatic Solid Tumors

Shots:

  • The P-I dose-escalation study will assess the safety- tolerability- and preliminary efficacy of DS-1055 in adult patients with r/r advanced or metastatic head and neck- gastric and esophageal cancers- and other tumor types
  • The focus of the study is to determine the maximum tolerated dose and recommended dose of DS-1055 for further study and is expected to enroll ~40 patients across the US and Japan. The company will integrate novel technologies with expertise in Ab biology to develop clinical candidates
  • DS-1055 is a mAb designed to target GARP and to promote antitumor immunity through the depletion of GARP positive Tregs

 ­ Ref: Daiichi Sankyo | Image: Medical Dialogues

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions